THE FACT ABOUT ABBV-744 IN COMBINATION WITH IMMUNOTHERAPY THAT NO ONE IS SUGGESTING

In Phase C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Members will receive treatment right up until ailment progression or even the members are unable to tolerate the study drugs.- Participant eaten grapefruit or grapefruit solutions within three days ahead of the main do